Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women

[1]  P. Wingo,et al.  Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma , 2002, Cancer.

[2]  P. Wingo,et al.  Hormone Replacement Therapy Regimens and Breast Cancer Risk , 2002 .

[3]  A. Berg,et al.  Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale , 2002, Annals of Internal Medicine.

[4]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[5]  B. Friedenson.  Oral contraceptives and the risk of breast cancer. , 2002, The New England journal of medicine.

[6]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[7]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[8]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[9]  W. Willett,et al.  Postmenopausal estrogen and progestin use in relation to breast cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  P. Wingo,et al.  The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. , 2002, Annals of epidemiology.

[11]  M. Pike,et al.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Haslam,et al.  Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model , 2001, Journal of cellular physiology.

[13]  S. Haslam,et al.  Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model. , 2001, American journal of obstetrics and gynecology.

[14]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[15]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[16]  R. Ross,et al.  RESPONSE: re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin , 2000, Journal of the National Cancer Institute.

[17]  G. Colditz,et al.  Bias in breast cancer analyses due to error in age at menopause. , 2000, American journal of epidemiology.

[18]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[19]  S. Haslam,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Hormone Replacement Therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation , 2022 .

[20]  E. Weiderpass,et al.  Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement , 1999, Cancer Causes & Control.

[21]  H. Adami,et al.  Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.

[22]  M. Pike,et al.  Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. , 1998, American journal of epidemiology.

[23]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[24]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[25]  R. Goldbohm,et al.  Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands Cohort Study , 1996, Cancer Causes & Control.

[26]  J. Stanford,et al.  Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. , 1995, JAMA.

[27]  R. Hoover,et al.  Oral contraceptives and breast cancer: results from an expanded case-control study. , 1989, British Journal of Cancer.

[28]  W. L. Beeson,et al.  Prospective study of exogenous hormone use and breast cancer in seventh‐day adventists , 1989, Cancer.

[29]  P M Layde,et al.  The evaluation of the data collection process for a multicenter, population-based, case-control design. , 1988, American journal of epidemiology.

[30]  J. Stanford,et al.  Breast Cancer Risk Among Women Under 55 Years of Age by Joint Effects of Usage of Oral Contraceptives and Hormone Replacement Therapy , 1998, Menopause.

[31]  N. Weiss,et al.  Oral contraceptives in relation to breast cancer. , 1993, Epidemiologic reviews.